VALPROATE-AFT sodium valproate 300 mg/3 ml solution for intravenous infusion or injection vials Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 300 mg/3 ml solution for intravenous infusion or injection vials

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

VALPROATE-AFT sodium valproate 400 mg/4 ml solution for intravenous infusion or injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 400 mg/4 ml solution for intravenous infusion or injection ampoules

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

VALPROATE-AFT sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection ampoules Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection ampoules

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; nitrogen; water for injections; monobasic potassium phosphate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.